Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lu-PSMA-617

Radiopharmaceutical · Cytotoxic, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer
1 Registered trials

What is Lu-PSMA-617?

Lu-PSMA-617 is a radiolabeled ligand, [177Lu]Lu-PSMA-617, delivered intravenously as an infusion. It is designed to bind prostate-specific membrane antigen, a tumor antigen, and is being studied in metastatic neuroendocrine prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Targets
prostate-specific membrane antigen (PSMA) (FOLH1)
Mechanism
Cytotoxic, directed at prostate-specific membrane antigen (PSMA) (FOLH1)
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06379217 Phase 1 Metastatic Neuroendocrine Prostate Cancer Terminated NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Neuroendocrine Prostate Cancer

Other drugs acting on FOLH1

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Lu-PSMA-617

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.